PANHEMATIN SUMMARY
PANHEMATIN (hemin for injection) is an enzyme inhibitor derived from processed red blood cells. Hemin for injection was known previously as hematin. The term hematin has been used to describe the chemical reaction product of hemin and sodium carbonate solution. Hemin is an iron containing metalloporphyrin.
PANHEMATIN (hemin for injection) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.
Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder.
Similar findings have been reported in other patients with acute intermittent porphyria, porphyria variegata and hereditary coproporphyria. PANHEMATIN is not indicated in porphyria cutanea tarda.
|
NEWS HIGHLIGHTS
Published Studies Related to Panhematin (Hemin)
General peroxidase activity of G-quadruplex-hemin complexes and its application in ligand screening. [2009.08.25]
DNA sequences with repetitive G-rich structural motifs, which form special structures called G-quadruplexes, widely exist in the human genome. Here we report the general peroxidase activity of G-quadruplex-hemin complexes and discuss the connection between peroxidase activity and G-quadruplex structures.
Possible relation of hemin-induced HO-1 expression to the upregulation of VEGF and BDNF mRNA levels in rat C6 glioma cells. [2009.05]
Glial cells are generally considered to contribute to retaining the integrity of neural function through the protection of neuronal cells against neurodegenerative insults and also expected to play a potential role in the protection of cerebrovascular systems from various toxic insults of hemorrhaged blood, thus proposing a possible implication of glial cells in the recovery of brain function from the damage caused by cerebral hemorrhage...
Protective effect of hemin against cadmium-induced testicular damage in rats. [2009.03.29]
The protective effect of hemin, the heme oxygenase-1 inducer, was investigated in rats with cadmium induced-testicular injury, in which oxidative stress and inflammation play a major role. Testicular damage was induced by a single i.p... It was concluded that hemin, through its antioxidant, anti-inflammatory and antiapoptotic effects, represents a potential therapeutic option to protect the testicular tissue from the detrimental effects of cadmium.
[Effect of hemin on severe acute pancreatitis-associated lung injury in rats and its mechanism] [2009.03]
OBJECTIVE: To investigate the effect of hemin on lung injury following severe acute pancreatitis (SAP) in rats and to explore its rudimentary mechanism... CONCLUSION: Hemin moderates the inflammatory reaction and decreases the lung injury following SAP, the mechanism of which may be closely related to the upregulation of expression of HO-1 mRNA, the inhibitory effect on NF-kappaB, and adjustment of cytokines.
Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. [2009.03]
Upregulating the heme oxygenase (HO) system removes the prooxidant heme, and thus is cytoprotective. Additionally, the products from the HO pathway including, carbon monoxide, bilirubin, and biliverdin, scavenge reactive oxygen species, inhibit lipid peroxidation, and suppress tissue inflammation, while the iron formed enhances the synthesis of the antioxidant ferritin.
Clinical Trials Related to Panhematin (Hemin)
Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS [Recruiting]
This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients
with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin®
(hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk
MDS.
The study will be conducted on an outpatient basis and will consist of the following:
- A Screening Period (within 28 days of the Day 1)
- Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study
medication
- An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2
through 8); partial and complete responders in any of the three cell lines may continue
treatment for an additional 4 weeks
- A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
|
